Precision Biosciences (DTIL) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Precision Biosciences is confronting a significant business risk following a Nasdaq Notice of non-compliance with the Minimum Bid Price Requirement. Despite a subsequent transfer to The Nasdaq Capital Market and an additional grace period, the company had to resort to a reverse stock split to bolster its stock price above the $1 threshold. While recently regaining compliance, the potential for future delisting looms, posing risks of impaired capital raising capabilities, reduced stock price, and diminished liquidity for shareholders. This precarious position highlights the volatility and uncertainty surrounding Precision Biosciences’ stock market standing.
Overall, Wall Street has a Moderate Buy consensus rating on DTIL stock based on 2 Buys.
To learn more about Precision Biosciences’ risk factors, click here.
